The impact of young age on breast cancer outcome

European Journal of Surgical Oncology

Volumn 36, Issue 7, 2010, Pages 639-645

  Livi, L ^a   Meattini, I ^a   Saieva, C ^b   Borghesi, S ^a   Scotti, V ^a   Petrucci, A ^a   Rampini, A ^a   Marrazzo, L ^a   Di Cataldo, V ^a   Bianchi, S ^a   Cataliotti, L ^a   Biti, G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ISPO   (Italy)

Author keywords

Anthracyclines; Breast cancer; Breast conserving surgery; Mastectomy; Radiation therapy; Young patients

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

ADULT; AGE FACTORS; AGE OF ONSET; ANALYSIS OF VARIANCE; ANTHRACYCLINES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77953916605     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.05.016     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
2. Zekri J.M., El-Helw L.M., Purohit O.P., et al. Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual function. Clin Oncol 20 (2008) 513-516
3. Jemal A., Thun M.J., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100 (2008) 1672-1694
4. Hickey M., Peate M., Saunders C.M., et al. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 15 (2009) 323-339
5. Olivotto I.A., Bajdik C.D., Plenderleith I.H., et al. Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 330 (1994) 805
6. Pagani O., and Goldhirsch A. Breast cancer in young women: climbing for progress in care and knowledge. Womens Health 2 (2006) 717-732
7. Aebi S., Gelber S., Castiglione-Gertsch M., et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet 355 (2000) 1869-1874
8. Henderson I.C., and Patek A.J. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 52 (1998) 261
9. Bernstein V. How young is too young? The impact of age on premenopausal breast cancer prognosis. Breast Cancer Res Treat 76 (2002) A137
10. Anders C.K., Hsu D.S., Broadwater G., et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26 (2008) 3324-3330
11. Rakha E.A., Reis-Filho J.S., and Ellis I.O. Basal-like breast cancer: a critical review. J Clin Oncol 26 (2008) 2568-2581
12. Vicini F.A., Kestin L.L., Goldstein N.S., et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol 18 (2000) 296-306
13. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 (1992) 71-85
14. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 19 (1998) 930-942
15. Fisher B., Brown A.M., Dimitrov N.V., et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8 (1990) 1483-1496
16. Levine M.N., Bramwell V.H., Pritchard K.I., et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16 (1998) 2651-2658
17. Hutchins L.F., Green S.J., Ravdin P.M., et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23 (2005) 8313-8321
18. Clarke M., Coates A.S., Darby S.C., et al., Early Breast Cancer Trialists' Collaborative Group. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371 (2008) 29-40
19. Papaldo P., Di Cosimo S., Ferretti G., et al. Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?. Breast 15 (2006) 269-272
20. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcome from adding sequential paclitaxel but not escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 21 (2003) 976-983
21. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358 (2008) 1663-1671
22. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
23. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 24 (2006) 1332-1341
24. Kyndi M., Overgaard M., Nielsen H.M., et al. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol 90 (2009) 74-79